Reused with permission from the American Society of Hematology. © 2025 The Authors. All rights reserved. Officially licensed by ASH for distribution via a corporate website by Kura.

American Society of Hematology
Helping hematologists conquer blood diseases worldwide



Ziftomenib in Combination with Venetoclax and Azacitidine in Relapsed/Refractory *NPM1*-m or *KMT2A*-r Acute Myeloid Leukemia: Updated Phase 1a/b Safety and Clinical Activity Results from KOMET-007

Ghayas C. Issa, MD[1], **Amir T. Fathi, MD[2]**, Amer M. Zeidan, MBBS, MHS[3], Harry Erba, MD, PhD[4], Gail J. Roboz, MD[5], Jessica K. Altman, MD[6], Keith W. Pratz, MD[7], Mark B. Juckett, MD, MHCM[8], Tara L. Lin, MD[9], Suresh Kumar Balasubramanian, MD[10], Anjali S. Advani, MD[11], Gary J. Schiller, MD[12], Neil D. Palmisiano, MDMS[13], Marcello Rotta, MD[14], Stephen A. Strickland, MD[15], Christine M. McMahon, MD[16], Yazan F. Madanat, MD[17], Talha Badar, MBBS, MD[18], Mohamad Khawandanah, MD[19], George Yaghmour, MD[20], James McCloskey, MD[21], James K. Mangan, MD, PhD[22], Antoine N. Saliba, MD[23], Ivana Gojo, MD[24], Diaa Osman, DO, MPH[25], Hongling Zhang, MS[26], Ying Tian, PhD[26], Marcie Riches, MD[26], Daniel Corum, PhD[26], Mollie Leoni, MD[26], Eunice S. Wang, MD[27]

[1]Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; [2]Massachusetts General Hospital, Harvard Medical School, Boston, MA; [3]Yale University and Yale Comprehensive Cancer Center, New Haven, CT; [4]Duke Cancer Institute, Durham, NC; [5]Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY; [6]Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; [7]Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; [8]Department of Hematology, University of Minnesota, Minneapolis, MN; [9]The University of Kansas Medical Center, Kansas City, KS; [10]Karmanos Cancer Institute, Wayne State University, Detroit, MI; [11]Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; [12]David Geffen School of Medicine at UCLA, Los Angeles, CA; [13]Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; [14]Colorado Blood Cancer Institute, Denver, CO; [15]SCRI at TriStar Centennial, Nashville, TN; [16]Anschutz Medical Campus, Division of Hematology, University of Colorado School of Medicine, Aurora, CO; [17]The University of Texas Southwestern Medical Center, Dallas, TX; [18]Mayo Clinic, Jacksonville, FL; [19]University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK; [20]University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; [21]John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; [22]UC San Diego Moores Cancer Center, La Jolla, CA; [23]Mayo Clinic, Rochester, MN; [24]Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; [25]Texas Oncology, Lakeway, TX; [26]Kura Oncology, Inc., San Diego, CA; [27]Roswell Park Comprehensive Cancer Center, Buffalo, NY

Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition on December 6–9, 2025 in Orlando, FL **#764**

Ziftomenib Targets the Menin Pathway, a Foundational Target in AML

- Leukemogenesis is driven by *NPM1* mutations or *KMT2A* rearrangements in ~35–40% of AML cases[1,2]
- Nearly half of AML patients will develop relapsed/refractory (R/R) disease within a year, with a <20% expected response rate following venetoclax/azacitidine (Ven/Aza) and progressively poorer outcomes with each subsequent line of therapy[3–6]
- **Ziftomenib** is a potent, highly selective, oral menin inhibitor with clinical activity as both monotherapy and in combination for adults with R/R *NPM1*-m or *KMT2A*-r AML[7,8]
- Ziftomenib monotherapy was approved for R/R *NPM1*-m AML by the US FDA on November 13, 2025

Ziftomenib Mechanism of Action[9–18]



1. Papaemmanuil E et al. *N Engl J Med*. 2016;374(23):2209–21. **2.** Issa GC et al. *Leukemia.* 2021;35:2482–95. **3.** Koschade SE et al. *Ann Hematol*. 2022;101(8):1703–10. **4.** Zainaldin C et al. *Leuk Lymphoma*. 2022;63(13):3245–8. **5.** Bewersdorf JP et al. *Leuk Res*. 2022;122:106942. **6.** Issa GC et al. *Blood Adv.* 2023;28:7(6):933–42. **7.** Wang ES et al. *Lancet Oncol*. 2024;25(10):1310–24. **8.** Fathi AT et al. *Blood*. 2024;144(Suppl_1):2880. **9.** Collins CT, Hess JL. *Curr Opin Hematol.* 2016;23(4)354–61. **10.** Lu R et al. *Cancer Cell.* 2016;30(1):92–107. **11.** Ferreira HJ et al. *Oncogene.* 2016;35(23):3079-82. **12.** Jeong M et al. *Nat Genet*. 2014;46(1):17-23. **13.** Wang GG et al. *Blood*. 2005;106(1):254–64. **14.** Chowdhury R et al. *EMBO Rep*. 2011;12(5):463–9. **15**. Schmidt L et al. *Leukemia*. 2019;33(7):1608–19. **16.** Xu H et al. *Cancer Cell.* 2016;30(6):863-78. **17.** Brunetti L et al. *Cancer Cell*. 2018;34(3):499–512. **18.** Wang XQD et al. *Cancer Discov.* 2023;13(3):724–45

AML, acute myeloid leukemia, US FDA, U.S. Food and Drug Administration

KOMET-007: Ongoing Phase 1 Combination Trial of Ziftomenib in R/R AML

Ziftomenib + Ven/Aza Combination (NCT05735184)



- Ziftomenib dosing started on Cycle 1 Day 8 and was administered continuously thereafter; Ven was administered per label in 28-day cycles; adjustments to cycle length based on Cycle 1 bone marrow biopsy results. Aza was administered on Cycle 1 Days 1–7; additional cycles based on bone marrow biopsy results
- **Here, we present updated safety and clinical activity in 83 patients with R/R AML treated with ziftomenib 600 mg once daily in combination with Ven/Aza**

[a]CR with full, partial, or incomplete hematologic recovery. [b]Locally assessed by next-generation sequencing, RT-qPCR, and multiparameter flow cytometry

AE, adverse event; CR, complete remission; CRc, composite complete remission; DoR, duration of response; MRD, measurable residual disease; ORR, overall response rate; RP2D, recommended phase 2 dose

KOMET-007: Safety and Efficacy Populations: R/R AML



[a]Patients who had ≥1 response assessment or who had died. [b]Patients who had not discontinued ziftomenib as of the data cutoff date. [c]Other reasons included: *NPM1*-m: physician decision (n=2), completed planned therapy (n=1), CNS disease (n=1), patient started another clinical trial (n=1), patient decision (n=3); *KMT2A*-r: patient deemed too ill to continue (n=1), physician decision (n=1). [d]Deaths included: *NPM1*-m: graft-vs-host disease (n=1), multiorgan failure (n=1), sepsis (n=1), respiratory failure (n=1); *KMT2A*-r: cardiac arrest (n=1), septic shock (n=1)

Data cutoff: Sep 24, 2025. CNS, central nervous system; HSCT, hematopoietic stem cell transplant

Baseline Characteristics and Disposition: R/R AML

n (%)	*NPM1*-m, 600 mg (N=51)	*KMT2A*-r, 600 mg (N=32)	All Patients, 600 mg (N=83)
Median age, years (range)	65 (25–85)	56 (19–76)	62 (19–85)
Female	23 (45)	17 (53)	40 (48)
Race			
White	37 (73)	22 (69)	59 (71)
Black / African American	5 (10)	2 (6)	7 (8)
Other / Non-White / Unknown	9 (18)	8 (25)	17 (20)
ECOG PS			
0	13 (26)	7 (22)	20 (24)
1	24 (47)	18 (56)	42 (51)
2	14 (28)	7 (22)	21 (25)
Selected co-mutations			
FLT3	21 (41)	3 (9)	24 (29)
IDH1/2	7 (14)	0	7 (8)
Both *FLT3* and *IDH1/2*	2 (2)	0	2 (2)
Median prior therapies (range)	1 (1–4)	1 (1–4)	1 (1–4)
Prior HSCT	10 (20)	6 (19)	16 (19)
Prior venetoclax	26 (51)	22 (69)	48 (58)
Prior menin inhibitors	1 (2)	7 (22)	8 (10)
Patients on treatment	16 (31)	5 (16)	21 (25)
Median follow-up, weeks (range)	26.3 (3.3–69.1)	16.9 (2.4–65.4)	24.6 (2.4–69.1)

Data cutoff: Sep 24, 2025. ECOG PS, Eastern Cooperative Oncology Group performance status

Safety and Tolerability of Ziftomenib with Ven/Aza: R/R AML

TEAEs in ≥25% of All Patients

n (%)	All TEAEs			Ziftomenib-Related TEAEs
	NPM1-m, 600 mg (N=51)	*KMT2A*-r, 600 mg (N=32)	All Patients, 600 mg (N=83)	All Patients, 600 mg (N=83)
Any grade	**49 (96)**	**32 (100)**	**81 (98)**	**48 (58)**
Nausea	19 (37)	15 (47)	34 (41)	13 (16)
Fatigue	25 (49)	6 (19)	31 (37)	12 (15)
Thrombocytopenia[a]	16 (31)	14 (44)	30 (36)	8 (10)
Febrile neutropenia	14 (28)	13 (41)	27 (33)	8 (10)
Diarrhea	17(33)	9 (28)	26 (31)	3 (4)
Leukopenia[b]	18 (35)	8 (25)	26 (31)	7 (8)
Neutropenia[c]	14 (28)	12 (38)	26 (31)	8 (10)
Vomiting	14 (28)	11 (34)	25 (30)	9 (11)
Anemia	11 (22)	13 (41)	24 (29)	8 (10)
Constipation	16 (31)	7 (22)	23 (28)	4 (5)
Pruritus	17 (33)	6 (19)	23 (28)	12 (15)
Decreased appetite	14 (28)	7 (22)	21 (25)	6 (7)
Hypokalemia	10 (20)	11 (34)	21 (25)	0

[a]Includes platelet count decreased and thrombocytopenia. [b]Includes white blood cell count decreased and leukopenia. [c]Includes neutrophil count decreased and neutropenia

Data cutoff: Sep 24, 2025. TEAE, treatment-emergent adverse event

Safety and Tolerability of Ziftomenib with Ven/Aza: R/R AML

Grade ≥3 TEAEs in ≥10% of All Patients

n (%)	All Grade ≥3 TEAEs			Grade ≥3 Ziftomenib-Related TEAEs
	NPM1-m, 600 mg (N=51)	*KMT2A*-r, 600 mg (N=32)	All Patients, 600 mg (N=83)	All Patients, 600 mg (N=83)
Grade ≥3	**46 (90)**	**30 (94)**	**76 (92)**	**33 (40)**
Thrombocytopenia[a]	15 (29)	13 (41)	28 (34)	7 (8)
Febrile neutropenia	14 (28)	12 (38)	26 (31)	8 (10)
Leukopenia[b]	18 (35)	8 (25)	26 (31)	7 (8)
Neutropenia[c]	14 (27)	12 (38)	26 (31)	8 (10)
Anemia	8 (16)	9 (28)	17 (21)	6 (7)
Sepsis	6 (12)	6 (19)	12 (15)	4 (5)

Ziftomenib-Related AEs of Interest

- No ziftomenib-related QTc prolongation was reported with the combination
- 2 (2%) patients discontinued due to ziftomenib-related AEs (both *KMT2A*-r; grade 4 sepsis and grade 3 stomatitis)
- 1 (1%) differentiation syndrome (*NPM1*-m, grade 3) successfully resolved with protocol-specified mitigation and patient resumed ziftomenib

[a]Includes platelet count decreased and thrombocytopenia. [b]Includes white blood cell count decreased and leukopenia. [c]Includes neutrophil count decreased and neutropenia
Data cutoff: Sep 24, 2025. QTc, corrected QT interval

Clinical Activity[a] of Ziftomenib with Ven/Aza: R/R AML

n (%)	*NPM1*-m, 600 mg (N=48)	*KMT2A*-r, 600 mg (N=32)
CRc	23 (48)	9 (28)
Median time to first CRc, weeks (range)	3.9 (2.7–15.6)	4.0 (2.6–18.9)
ORR	31 (65)	13 (41)
CR	13 (27)	2 (6)
CRh	6 (13)	5 (16)
CRi	4 (8)	2 (6)
MLFS	7 (15)	4 (13)
PR	1 (2)	0
NR	13 (27)	17 (53)
NE[b]	4 (8)	2 (6)
MRD negativity rate[c], n/N (%)	12/20 (60)	3/7 (43)
Median time to first MRD negativity, weeks (range)	8.8 (2.9–21.4)	8.1 (7.7–18.9)

- For *NPM1*-m, CR/CRh rates were 46% (13/28), 42% (5/12), and 14% (1/7) for patients with 1, 2, and ≥3 prior lines of therapy, respectively

[a]In patients with ≥1 response assessment or had died. [b]Not evaluable (1 *NPM1*-m) or not done (3 *NPM1*-m, 2 *KMT2A*-r). [c]Locally assessed among CRc responders (NGS, RT-qPCR, FISH, flow cytometry)
Data cutoff: Sep 24, 2025. CR / CRh / CRi, complete remission with full / partial / incomplete hematologic recovery; CRc, composite complete remission; MLFS, morphologic leukemia-free state; MRD, measurable residual disease; NE, not evaluable; NR, no response; ORR, objective response rate; PR, partial response

Clinical Activity[a] by Prior Venetoclax

n (%)	No Prior Ven		Prior Ven	
	NPM1-m, 600 mg (N=23)	*KMT2A*-r, 600 mg (N=10)	*NPM1*-m, 600 mg (N=25)	*KMT2A*-r, 600 mg (N=22)
CRc	16 (70)	6 (60)	7 (28)	3 (14)
Median time to first CRc, weeks (range)	3.8 (2.7–15.6)	3.4 (2.6–15.1)	4.3 (2.9–14.3)	9.3 (7.7–18.9)
ORR	19 (83)	7 (70)	12 (48)	6 (27)
CR	10 (44)	2 (20)	3 (12)	0
CRh	4 (17)	3 (30)	2 (8)	2 (9)
CRi	2 (9)	1 (10)	2 (8)	1 (5)
MLFS	3 (13)	1 (10)	4 (16)	3 (14)
PR	0	0	1 (4)	0
NR	4 (17)	3 (30)	9 (36)	14 (64)
NE	0	0	4 (16)	2 (9)
MRD negativity rate[b], n/N (%)	7/13 (54)	1/4 (25)	5/7 (71)	2/3 (67)
Time to first MRD negativity, median (range), weeks	11.7 (3.1–16.6)	8.1 (8.1–8.1)	3.0 (2.9–21.4)	13.3 (7.7–18.9)

[a]In patients with ≥1 response assessment or had died. [b]Locally assessed among CRc responders

Data cutoff: Sep 24, 2025. CR / CRh / CRi, complete remission with full / partial / incomplete hematologic recovery; CRc, composite complete remission; MLFS, morphologic leukemia-free state; MRD, measurable residual disease; NE, not evaluable; NR, no response; ORR, objective response rate; PR, partial response

Duration of Treatment and Clinical Outcomes: R/R AML

NPM1-m



For *NPM1*-m, after a median follow-up of 27.4 weeks (range 3.3–69.1):

- Median duration of CRc was **39.9 weeks** (95% CI 16.1–NE)
  - Ven-naïve: 39.9 weeks (95% CI 12.9–NE)
- 14 *NPM1*-m patients received HSCT, and 5 went onto ziftomenib maintenance
- Median OS was **54.9 weeks** (95% CI 32.0–NE)

Data cutoff: Sep 24, 2025.

CR / CRh / CRi, complete remission with full / partial / incomplete hematologic recovery; CRc, composite complete remission
MLFS, morphologic leukemia-free state; HSCT, hematopoietic stem cell transplant; OS, overall survival; PR, partial response

Duration of Treatment and Clinical Outcomes: R/R AML

KMT2A-r



For *KMT2A*-r, after a median follow-up of 16.9 weeks (range 2.4–65.4):

- Median duration of CRc was **12.4 weeks** (95% CI 0.9–NE)
  - Ven-naïve: 10.0 weeks (95% CI 0.9–NE)
- 2 *KMT2A*-r patients received HSCT, and both went onto ziftomenib maintenance
- Median OS was **21.1 weeks** (95% CI 12.4–64.9)

Data cutoff: Sep 24, 2025.

CR / CRh / CRi, complete remission with full / partial / incomplete hematologic recovery; CRc, composite complete remission
MLFS, morphologic leukemia-free state; HSCT, hematopoietic stem cell transplant; OS, overall survival; PR, partial response

ANC and Platelet Recovery in CRc Responders: R/R AML

Median (range)	All Patients, 600 mg (N=32)[a]
Days to ANC recovery ≥0.5 × 10^9/L	36 (0–136)
Days to ANC recovery ≥1.0 × 10^9/L	45 (34–145)
Days to platelet count recovery ≥50 × 10^9/L	27 (0–139)
Days to platelet count recovery ≥100 × 10^9/L	28 (0–243)

- Times to neutrophil and platelet count recovery were comparable to those for Ven/Aza alone[1]

[a]Subset of patients who reached cutoff

1. Aldoss et al. *Haematologica*. 2018;103(9):e404–7.

Data cutoff: Sep 24, 2025. ANC, absolute neutrophil count

Conclusions

- **In the ongoing KOMET-007 study, ziftomenib 600 mg once daily in combination with Ven/Aza was well tolerated in R/R *NPM1*-m or *KMT2A*-r AML**
  - Low rates of ziftomenib-related myelosuppression
  - No ziftomenib-related QTc prolongation was reported
  - One case of differentiation syndrome (*NPM1*-m, grade 3) successfully resolved with protocol-specified mitigation, and patient resumed ziftomenib
- **Encouraging clinical activity was demonstrated in patients with R/R *NPM1*-m or *KMT2A*-r AML, including in patients with prior venetoclax exposure**
  - *NPM1*-m: 65% ORR and 48% CRc, with a median DoR of 39.9 weeks
    - Ven-naïve: 83% ORR and 70% CRc; Ven-exposed: 48% ORR and 28% CRc
  - *KMT2A*-r: 41% ORR and 28% CRc, with a median DoR of 12.4 weeks
    - Ven-naïve: 70% ORR and 60% CRc
- **Taken together, these data support further investigation of ziftomenib-based combinations in R/R *NPM1*-m and *KMT2A*-r AML**

Acknowledgments

- We would like to thank all the patients, their families, and their caregivers, as well as the KOMET-007 study investigators and their study teams
- This study was sponsored by Kura Oncology, Inc., in partnership with Kyowa Kirin group
- Medical writing support was provided by Envision Pharma Group, with funding from Kura Oncology, Inc.

Slides can be accessed through this Quick Response (QR) code.

Copies obtained are for personal use only.

Reused with permission from the American Society of Hematology. © 2025 The Authors. All rights reserved. Officially licensed by ASH for distribution via a corporate website by Kura